Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

20th October 2017 – Bio-Link has been engaged by Heptares Therapeutics to identify clinical collaborators

Heptares Therapeutics, a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs) has engaged Bio-Link to identify clinical collaborators for clinical studies investigating the role of individual GPCRs in human health and there role in human pathogenesis. Review the opportunity here.

19th September 2017 – Oncology Venture: Early data from ongoing LiPlaCis® Ph1/2 study show response and clinical benefits in hard to treat patients with metastatic Breast Cancer

Bio-Link’s client Oncology Venture has released promising early data from the ongoing LiPlaCis® Phase 1/2 study in hard to treat patients with metastatic Breast Cancer, reporting treatment response and clinical benefits. Patients were selected as likely responders using a proprietary Drug Response Predictor (DRPTM) technology. Read more here.

20th July 2017 – Oncology Venture receives option right to execute licence for clinical-stage cancer therapeutic from Novartis.

Oncology Venture, a precision oncology biopharmaceutical company and Bio-Link client, has entered an agreement with pharmaceutical giant Novartis to evaluate the potential of in-licensing an undisclosed, clinical-stage cancer therapeutic. Under the terms of the deal, Oncology Venture receives an option right to execute an exclusive licence to develop and commercialise the small molecule kinase inhibitor, which has previously been explored in multiple therapeutic indications including solid tumours.

Oncology Venture will use its Drug Response Predictor (DRP™) technology to evaluate whether it can validate a companion diagnostic for Novartis’ drug and predict which patients are likely to respond to treatment. Dr Peter Buhl Jensen, CEO of Oncology Venture, is “confident that by using our DRP™ technology to select patients we will raise the chances of success for the molecule in clinical development.” Read the full press release here.

17th July 2017 – Bio-Link’s Dr Lieven Huang Attending ‘Business of Regenerative Medicine’ in Toronto This Week

After winning a CCRM Australia grant, Bio-Link’s Dr Lieven Huang is attending the 2017 edition of ‘Business of Regenerative Medicine’ in Toronto, which is focused on the latest in commercialising regenerative medicine and stem cell therapies. The event is co-hosted by the Centre for Commercialization of Regenerative Medicine (CCRM) and the Rotman School of Management. More information about the event here.


10th July 2017 – First Dosing in a Phase 1b Combination Trial of the Dynamin Inhibitor Prochlorperazine and Anti-EGFR Monoclonal Antibody Cetuximab in Head and Neck Squamous Cell Carcinoma Patients.

The first two patients have been dosed in a phase Ib clinical trial at the Princess Alexandra Hospital (PAH, Brisbane, Australia), evaluating the efficacy of co-treatment of the anti-psychotic / anti-emetic drug prochlorperazine (Stemetil®) with anti-EGFR monoclonal antibody (mAb) cetuximab in head and neck squamous cell carcinoma (HNSCC) patients (HREC/16/QPAH/825). Prochlorperazine is a potent off-target inhibitor of the enzyme dynamin II. To learn more, please click here.